AEON Biopharma, Inc.

AEON NYSE SEC CIK 1837607
Follow AEON Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income $2.5M +154.3% vs same quarter last year
EPS, diluted $0.01 +102.6% vs same quarter last year
Operating cash flow −$5.7M −120.5% vs same quarter last year
Operating income −$4.5M −79.8% vs same quarter last year
Net income by quarter
$2.1M
$9.1M
−$6.6M
−$4.5M
−$37.1M
−$11.8M
−$1.2M
$2.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$75M−$50M−$25M$0$25M$50MFY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$39.2M
FY24$42M
FY23-
FY22−$52.6M
FY21$8.2M
FY20-